NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Aflibercept (Eylea): Treatment of Neovascular (Wet) Age-Related Macular Degeneration (wAMD) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug.

Cover of Aflibercept (Eylea)

Aflibercept (Eylea): Treatment of Neovascular (Wet) Age-Related Macular Degeneration (wAMD) [Internet].

Show details

Table 9Cost Comparison Table for Anti-VEGF Therapies For Neovascular (Wet) Age-Related Macular Degeneration

Drug/
Comparator
StrengthDosage
Form
Price ($)Recommended DoseAnnual Cost Per Eye
($)
Aflibercept (Eylea)40 mg/mL0.05 mL vial1,418.00aYear 1: 2 mg monthly for 3 months, then 2 mg every 2 months

Year 2: Individualized regime
9,926 (7 injections)

5,672 to 8,508 (4 to 6 injections)
Ranibizumab (Lucentis)10 mg/mL0.23 mL vial1,575.00b0.5 mg monthly

Based on listing recommendationc Year 1

Years 2 and 3
18,900 (12 injections)

14,175 (9 injections)

9,450 (6 injections)
Pegaptanib sodium (Macugen)0.3 mg90 mcL pre-filled syringe1,013.91d0.3 mg every 6 weeks8,839

CDR = CADTH Common Drug Review; VEGF = vascular endothelial growth factor; wAMD = neovascular (wet) age-related macular degeneration.

Note: Excess medication in vials or syringes is assumed to be wasted for all comparators.

a

Manufacturer’s confidential submitted price.

b

Ontario Formulary (June 2014).

c

Recommended reimbursement maximum as detailed in CDR recommendation for Lucentis for wAMD (March 27, 2008).

d

Quebec Formulary (June 2014).

From: APPENDIX 1, COST COMPARISON TABLE OF ANTI-VEGF THERAPIES FOR WAMD

Copyright © CADTH 2015.

You are permitted to make copies of this document for non-commercial purposes, provided it is not modified when reproduced and appropriate credit is given to CADTH. You may not otherwise copy, modify, translate, post on a website, store electronically, republish, or redistribute any material from this document in any form or by any means without the prior written permission of CADTH.

Please contact CADTH’s Vice-President of Corporate Services at ac.htdac@secivresetaroproc with any inquiries about this notice or other legal matters relating to CADTH’s services.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Views

  • Cite this Page

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...